Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, from 13:30 to 17:00 UK time at the London Stock Exchange. The event will be held in person and via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. Details for accessing the live webcast are available here.
The capital markets day comes at a pivotal time for Sandoz, which is positioning itself to capitalize on what it calls the "golden decade for biosimilars." Biosimilars, which are nearly identical copies of biologic drugs, offer significant cost savings to healthcare systems and expanded patient access. Sandoz has been a pioneer in this space, celebrating 20 years of biosimilars in 2026.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. This visit will provide deeper insight into the company’s new biosimilars development and supply-chain hub. Attendance will also be by invitation only, and the event will not be webcasted.
The announcements underscore Sandoz’s strategic focus on biosimilars as a key growth driver. With a portfolio of approximately 1,300 medicines and net sales of USD 11.1 billion in 2025, Sandoz is leveraging its scale and expertise to lead in affordable medicines. The company’s purpose is "pioneering access for patients," and it reaches over one billion patients annually.
The capital markets day and site visit are expected to provide investors with a clearer picture of Sandoz’s strategy to maximize value in the biosimilars market, which is projected to grow substantially as patents on biologic drugs expire. Sandoz’s forward-looking statements caution that actual results may vary due to risks such as global economic conditions, exchange rates, and competitive activities.
